Showing 2 posts of 2 posts found.
GSK has set out plans to boost its flagging performance with the launch of up to 20 new drugs by …
Pfizer had a takeover approach rejected by fellow pharma giant GlaxoSmithKline, before turning its attentions to Allergan, it has emerged. …
How chronic disease creates opportunity on diagnostic and therapeutic pipelines
EnteroBiotix appoints former GSK Chief Medical Officer to board
Stryker invests US$400m in CMR Surgical and secures option to acquire business
AI: an early warning system for patient safety
Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial